AR122266A1 - Anticuerpos anti-sema3a y sus usos para tratar enfermedades oculares - Google Patents

Anticuerpos anti-sema3a y sus usos para tratar enfermedades oculares

Info

Publication number
AR122266A1
AR122266A1 ARP200101337A ARP200101337A AR122266A1 AR 122266 A1 AR122266 A1 AR 122266A1 AR P200101337 A ARP200101337 A AR P200101337A AR P200101337 A ARP200101337 A AR P200101337A AR 122266 A1 AR122266 A1 AR 122266A1
Authority
AR
Argentina
Prior art keywords
seq
amino acid
acid sequence
sema3a
variable region
Prior art date
Application number
ARP200101337A
Other languages
English (en)
Spanish (es)
Inventor
Leo Thomas
Rachel Rebecca Barrett
Kristin Laura Bovat
Rajkumar Ganesan
Priyanka Gupta
Fei Han
Dongmei Liu
Juergen Prestle
Sanjaya Singh
Sathyadevi Venkataramani
Helen Haixia Wu
Nina Zippel
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AR122266A1 publication Critical patent/AR122266A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ARP200101337A 2019-05-09 2020-05-08 Anticuerpos anti-sema3a y sus usos para tratar enfermedades oculares AR122266A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19173454 2019-05-09

Publications (1)

Publication Number Publication Date
AR122266A1 true AR122266A1 (es) 2022-08-31

Family

ID=66476463

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200101337A AR122266A1 (es) 2019-05-09 2020-05-08 Anticuerpos anti-sema3a y sus usos para tratar enfermedades oculares

Country Status (27)

Country Link
US (3) US11267880B2 (cg-RX-API-DMAC10.html)
EP (1) EP3966239A1 (cg-RX-API-DMAC10.html)
JP (2) JP7314310B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220007128A (cg-RX-API-DMAC10.html)
CN (1) CN113795509A (cg-RX-API-DMAC10.html)
AR (1) AR122266A1 (cg-RX-API-DMAC10.html)
AU (1) AU2020267874B2 (cg-RX-API-DMAC10.html)
BR (1) BR112021019854A2 (cg-RX-API-DMAC10.html)
CA (1) CA3137377A1 (cg-RX-API-DMAC10.html)
CL (1) CL2021002795A1 (cg-RX-API-DMAC10.html)
CO (1) CO2021014768A2 (cg-RX-API-DMAC10.html)
CR (1) CR20210559A (cg-RX-API-DMAC10.html)
DO (1) DOP2021000226A (cg-RX-API-DMAC10.html)
EA (1) EA202193038A1 (cg-RX-API-DMAC10.html)
EC (1) ECSP21082527A (cg-RX-API-DMAC10.html)
IL (1) IL287758A (cg-RX-API-DMAC10.html)
JO (1) JOP20210300A1 (cg-RX-API-DMAC10.html)
MA (1) MA55872A (cg-RX-API-DMAC10.html)
MX (1) MX2021013671A (cg-RX-API-DMAC10.html)
MY (1) MY206253A (cg-RX-API-DMAC10.html)
PE (1) PE20220287A1 (cg-RX-API-DMAC10.html)
PH (1) PH12021552776A1 (cg-RX-API-DMAC10.html)
SA (1) SA521430793B1 (cg-RX-API-DMAC10.html)
SG (1) SG11202110842QA (cg-RX-API-DMAC10.html)
TW (1) TWI836069B (cg-RX-API-DMAC10.html)
UA (1) UA129953C2 (cg-RX-API-DMAC10.html)
WO (1) WO2020225400A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021013671A (es) 2019-05-09 2021-12-10 Boehringer Ingelheim Int Anticuerpos anti-sema3a y sus usos para tratar enfermedades oculares.
US20220127344A1 (en) * 2020-10-23 2022-04-28 Boehringer Ingelheim International Gmbh Anti-sema3a antibodies and their uses for treating a thrombotic disease of the retina
IL307233A (en) * 2021-03-30 2023-11-01 Bayer Ag Anti-SEMA3A antibodies and uses thereof
CN116790610B (zh) * 2023-05-18 2024-09-20 四川大学 一种治疗骨科疾病的基因及以aav为载体的基因治疗药物

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
WO1990003430A1 (en) 1988-09-23 1990-04-05 Cetus Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
ATE139900T1 (de) 1992-11-13 1996-07-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
EP2497498A4 (en) 2009-11-05 2013-04-17 Univ Osaka THERAPEUTIC ACTIVE FOR AUTOIMMUNE DISEASES OR ALLERGIES AND METHOD FOR SCREENING AFTER THE THERAPEUTIC ACTIVE SUBSTANCE
WO2013005603A1 (ja) * 2011-07-01 2013-01-10 公立大学法人横浜市立大学 結膜におけるアレルギー性炎症の予防及び／又は治療剤
WO2014123186A1 (ja) 2013-02-06 2014-08-14 公立大学法人横浜市立大学 抗セマフォリン３ａ抗体、並びにこれを用いたアルツハイマー病及び免疫・炎症性疾患の治療
EP2958580B8 (en) 2013-02-21 2026-01-14 RSEM, Limited Partnership Inhibition of sema3a in the prevention and treatment of ocular hyperpermeability
AU2015311563B2 (en) 2014-09-05 2019-11-28 Rsem, Limited Partnership Compositions and methods for treating and preventing inflammation
AU2016346595B2 (en) 2015-10-27 2019-11-14 Pangen Biotech Inc. Antibody to be cross-linked to human and mouse Sema3A, and use thereof
KR101854529B1 (ko) * 2015-10-27 2018-05-04 (주) 팬젠 인간 및 마우스 Ｓｅｍａ３Ａ에 교차결합하는 항체 및 그의 용도
US10604571B2 (en) 2015-10-27 2020-03-31 Samsung Life Public Welfare Foundation Antibody to human and mouse SEMA3A and use thereof
MX2021013671A (es) 2019-05-09 2021-12-10 Boehringer Ingelheim Int Anticuerpos anti-sema3a y sus usos para tratar enfermedades oculares.

Also Published As

Publication number Publication date
TW202108621A (zh) 2021-03-01
TWI836069B (zh) 2024-03-21
EA202193038A1 (ru) 2022-03-30
UA129953C2 (uk) 2025-09-24
BR112021019854A2 (pt) 2022-02-15
JP2022531698A (ja) 2022-07-08
SA521430793B1 (ar) 2024-03-28
JP7314310B2 (ja) 2023-07-25
SG11202110842QA (en) 2021-10-28
MY206253A (en) 2024-12-05
EP3966239A1 (en) 2022-03-16
MX2021013671A (es) 2021-12-10
US20200385446A1 (en) 2020-12-10
US11267880B2 (en) 2022-03-08
CN113795509A (zh) 2021-12-14
JOP20210300A1 (ar) 2023-01-30
PH12021552776A1 (en) 2022-09-19
JP7638332B2 (ja) 2025-03-03
US20240336674A1 (en) 2024-10-10
WO2020225400A1 (en) 2020-11-12
CL2021002795A1 (es) 2022-08-05
MA55872A (fr) 2022-03-16
NZ780763A (en) 2025-09-26
US20220144929A1 (en) 2022-05-12
DOP2021000226A (cg-RX-API-DMAC10.html) 2021-12-15
AU2020267874A1 (en) 2021-10-28
IL287758A (en) 2022-01-01
KR20220007128A (ko) 2022-01-18
CA3137377A1 (en) 2020-11-12
JP2023130473A (ja) 2023-09-20
AU2020267874B2 (en) 2026-07-09
CR20210559A (es) 2021-12-23
CO2021014768A2 (es) 2021-11-19
ECSP21082527A (es) 2021-12-30
PE20220287A1 (es) 2022-02-25

Similar Documents

Publication Publication Date Title
CL2024002250A1 (es) Uso de anticuerpo anti-vd1 para tratar cáncer, una enfermedad infecciosa o una enfermedad inflamatoria.
AR111630A1 (es) ANTICUERPOS ANTI-SIRPa
MY199530A (en) Anti-cd3epsilon antibodies
PE20200173A1 (es) Anticuerpos anti-trkb
RU2018133708A (ru) Антитела, обладающие специфичностью к btla, и их использование
JOP20210297A1 (ar) مواد وطرق لحث المناعة التي تساهم فيها الخلايا التائية
AR120883A1 (es) Anticuerpos anti-fgfr2b
AR108663A1 (es) ANTICUERPOS CONTRA a-SINUCLEÍNA Y SUS USOS
AR109715A1 (es) Anticuerpos anti-cd27
MX2021007006A (es) Anticuerpo anti-calicreina-2 humanizado.
AR105267A1 (es) Anticuerpos de unión a tau
AR120886A1 (es) Anticuerpos anti-fgfr2b
PE20220287A1 (es) Anticuerpos anti-sema3a y sus usos para tratar enfermedades oculares
CO2023000557A2 (es) Anticuerpos y métodos para tratar enfermedades asociadas a claudina
NZ599438A (en) Humanized antibodies against human il-22ra
ECSP18084153A (es) Anticuerpos anti-BASIGIN humanizados y uso de los mismos
MX2024001067A (es) Composicion farmaceutica y uso.
AR120884A1 (es) Anticuerpos anti-fgfr2b
UY38807A (es) Proteínas de unión a antígeno anti-il13
AR123671A1 (es) Anticuerpo fn14 anti-humano
RU2015150723A (ru) Моноклональное антитело против cxcr5
MX2022003074A (es) Anticuerpos anti-cd371, y usos de los mismos.
CL2024003952A1 (es) Anticuerpos humanizados o fragmentos funcionales de los mismos contra antígenos tumorales
MX2018004071A (es) Polipeptidos como anticuerpos y usos de los mismos.
PE20220809A1 (es) Anticuerpos anti-angpt2